The studies reported so far have been conducted in healthy older subjects with no major functional impairments. This study population provides relevant information for a chronic treatment aimed at the general older population, but it is not yet clear whether this is the appropriate target population. It may be that a more appropriate or cost-effective use of GHRH in the elderly will be in much more focused or short-term settings—for example, in the frail elderly, in patients with serious debilitating illness, or in the treatment of patients with fractures, wounds, or burns, to assist in bringing them to a point when they can enter an active rehabilitation or exercise program. These are also settings in which the utility of GH and of other secretagogues is being investigated, but there are no published data on the effects of GHRH in these contexts.
Was this article helpful?